CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment

Jun 3, 2021

CORAT secures 12,7 Mio € from Lower Saxony State, private investors, and the German Ministry of Research and Education (BMBF).

NBank Capital and private investors from Braunschweig, each having participated in previous financing rounds, renewed their investments. The current round of financing includes additional new investors from Braunschweig. Additionally, CORAT Therapeutics GmbH is to receive up to seven million euros from the federal funding program „Research and development of urgently needed therapeutics against SARS-CoV-2“ to support clinical development of COR-101.

CORAT has completed all the necessary development steps on schedule so far. Now, it is important to maintain the fast development and to continue with the necessary clinical trials without delay. The government of Lower Saxony is excited to continue this success story.

Dr. Bernd Althusmann, Lower Saxony State Secretary of Economics

Press release (PDF): englishgerman

Share this entry

Latest news

TV report on COR-101

TV report on COR-101

CORAT's CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed at the...

read more